Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for APG279 (APG777 + APG990) in Atopic Dermatitis (AD). The expected timing is based on the latest available company guidance and may change.
3/3/25- Initiate a head-to-head Phase 1b trial against DUPIXENT in 2025. 7/7/25- Ph1b initiated; readout expected in H2 2026. 11/10/25:- Interim Ph1b head-to-head AD readout with DUPIXENT reiterated for H2 2026. 01/06/26:- Ph1b head-to-head AD trial upsized to ~80 patients; readout remains expected in H2 2026. 03/02/26:- APG279 head-to-head AD Ph1b trial ongoing; interim data readout reiterated for H2 2026. 05/11/26:- Ph1b APG279 AD head-to-head trial fully enrolled (86 patients); 24-week interim data expected H2 2026. 08/10/26:- Ph1b head-to-head AD interim data remains expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.